Skip to main content
    L

    Lifecore Biomedical Inc. (LFCR)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $6.42
    -0.01 (-0.08%)

    Market Cap: $243.36M

    Last updated: Nov 17, 2026 at 11:03 AM ET

    Lifecore Biomedical Inc. (LFCR) Financials: Revenue, Profit and Cash Flow

    Updated Sep 30, 2026. Financial statements from company filings, amounts in US dollars.

    Lifecore Biomedical reported revenue of $128.87M for the fiscal year ended May 31, 2025, up 0.5% from the year before. That year, net income was -$38.72M with a net margin of -30.0%, operating cash flow was -$206.00K and free cash flow was -$13.62M. The quarter ended Sep 30, 2026 had revenue of $25.32M and net income of -$40.08M.

    Revenue and Margins

    The operating margin was -13.4% in the fiscal year ended May 2025. Over the 9 years to May 2025, revenue fell from $476.92M, a compound annual decline of 13.5%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    May 2025$128.87M+0.5%31.3%-13.4%-30.0%
    May 2024$128.26M+24.2%32.6%-6.9%9.4%
    May 2023$103.27M-7.2%27.1%-21.1%-96.4%
    May 2022$111.27M+10.3%35.1%-10.6%-104.9%
    May 2021$100.87M-37.0%38.6%-8.7%-32.0%
    May 2020$160.07M-71.3%24.6%-16.2%-23.9%
    May 2019$557.56M+6.4%14.5%1.0%0.1%
    May 2018$524.23M+11.6%14.9%2.6%4.8%
    May 2017$469.78M-1.5%16.9%3.1%2.3%
    May 2016$476.92MN/A14.0%-4.3%-2.4%
    Annual, fiscal years ended May 2016 to May 2025

    Income Statement

    In the fiscal year ended May 2025, the company posted a net loss after a profit the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemMay 2025May 2024May 2023May 2022May 2021May 2020May 2019May 2018May 2017May 2016
    Revenue$128.87M$128.26M$103.27M$111.27M$100.87M$160.07M$557.56M$524.23M$469.78M$476.92M
    Cost of revenue$88.57M$86.41M$75.28M$72.20M$61.94M$120.68M$476.56M$445.89M$390.56M$410.14M
    Gross profit$40.30M$41.85M$27.98M$39.07M$38.94M$39.39M$81.00M$78.34M$79.21M$66.78M
    Research and development$8.26M$8.57M$8.74M$7.84M$6.68M$7.58M$11.47M$12.80M$9.47M$7.23M
    Operating income-$17.25M-$8.84M-$21.80M-$11.79M-$8.82M-$25.88M$5.47M$13.59M$14.67M-$20.63M
    Net income-$38.72M$12.01M-$99.56M-$116.72M-$32.29M-$38.19M$411.00K$24.92M$10.68M-$11.45M
    EBITDA-$8.81M$35.56M-$9.43M$12.84M$75.00K-$7.23M$22.30M$28.90M$26.25M-$10.03M
    Fiscal years ended May 2016 to May 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Feb 2026Nov 2025Sep 2025Aug 2025May 2025Feb 2025Nov 2024Aug 2024May 2024
    Revenue$25.32M$34.17M$23.19M$23.19M$34.17M$31.11M$23.19M$36.44M$35.15M$32.56M$24.70M$37.88M
    Gross profit$6.83M$12.07M$4.46M$4.46M$12.07M$7.79M$4.46M$13.98M$9.85M$11.08M$5.39M$17.27M
    Operating income-$894.00K$2.57M-$4.67M-$4.67M$2.57M-$3.07M-$4.67M$5.33M-$9.03M-$1.96M-$11.58M$2.15M
    Net income-$40.08M-$6.16M-$14.98M-$14.98M-$6.16M-$9.99M-$14.98M-$1.15M-$14.77M-$6.57M-$16.23M-$7.08M
    Last 12 quarters

    Balance Sheet

    As of May 2026, total debt of $136.91M exceeded cash and equivalents by $119.44M. Shareholder equity was negative, at -$14.20M, as total liabilities of $246.38M exceeded total assets of $232.18M.

    Annual

    Line itemMay 2026Dec 2025May 2025May 2024May 2023May 2022May 2021May 2020May 2019May 2018
    Total assets$232.18M$232.18M$232.18M$253.96M$253.54M$274.70M$501.88M$541.31M$519.09M$404.70M
    Current assets$82.29M$82.29M$82.29M$81.03M$93.88M$116.67M$145.30M$157.11M$133.04M$97.06M
    Cash and equivalents$17.47M$17.47M$17.47M$8.46M$19.09M$991.00K$763.00K$360.00K$1.08M$2.90M
    Total liabilities$246.38M$198.12M$198.12M$200.06M$218.46M$186.88M$299.94M$310.27M$248.95M$152.14M
    Short-term debt$1.33MN/A$3.82M$4.91M$580.00K$138.18M$29.00M$88.95M$61.79M$31.94M
    Long-term debt$135.59M$141.28M$141.28M$123.72M$101.06M$0$164.90M$101.36M$87.19M$37.36M
    Shareholder equity-$14.20M-$14.20M-$14.20M$11.31M-$4.23M$87.82M$201.95M$231.04M$270.14M$252.56M
    Fiscal years ended May 2018 to May 2026

    Quarterly

    Line itemSep 2026Jun 2026May 2026Mar 2026Feb 2026Dec 2025Nov 2025Aug 2025May 2025Feb 2025Nov 2024Aug 2024
    Total assets$228.30M$229.50M$232.18M$225.50M$225.50M$232.18M$229.50M$225.50M$239.34M$237.69M$255.39M$246.82M
    Total liabilities$250.58M$213.41M$246.38M$204.72M$204.72M$198.12M$213.41M$204.72M$238.01M$190.27M$195.63M$207.32M
    Cash and equivalents$23.04M$17.24M$17.47M$20.80M$20.80M$17.47M$17.24M$20.80M$8.27M$5.42M$9.46M$5.52M
    Shareholder equity-$73.40M-$34.09M-$14.20M-$28.44M$20.78M-$14.20M-$34.09M-$28.44M$1.34M$2.23M$15.45M-$3.94M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended May 2025.

    Annual

    Line itemMay 2025May 2024May 2023May 2022May 2021May 2020May 2019May 2018May 2017May 2016
    Operating cash flow-$206.00K$257.00K-$17.44M-$22.59M$16.47M-$17.04M$16.02M$19.78M$29.84M$20.76M
    Capital expenditures$13.41M$18.39M$21.48M$29.94M$25.22M$26.69M$44.73M$33.59M$23.00M$39.70M
    Free cash flow-$13.62M-$18.14M-$38.92M-$52.53M-$8.75M-$43.73M-$28.71M-$13.81M$6.83M-$18.93M
    Dividends paidN/A$3.08M$274.00KN/AN/A$212.00K$700.00K$115.00K$166.00K$248.00K
    Investing cash flow-$6.42M-$18.39M-$4.81M$79.96M-$12.31M-$23.89M-$96.80M-$35.59M-$25.42M-$40.42M
    Financing cash flow$6.42M$7.51M$39.70M-$57.02M-$3.42M$40.02M$79.03M$13.29M-$8.80M$15.42M
    Fiscal years ended May 2016 to May 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Feb 2026Nov 2025Sep 2025Aug 2025May 2025Feb 2025Nov 2024Aug 2024May 2024
    Operating cash flow$6.95M-$2.19M$4.70M$4.70M-$2.19M$5.96M$4.70M$7.16M$1.20M$7.16M-$613.00K$8.72M
    Capital expenditures$912.00K$513.00K$1.12M$1.12M$513.00K$2.24M$1.12M$4.13M$5.46M$4.13M$3.42M$2.71M
    Free cash flow$6.03M-$2.70M$3.58M$3.58M-$2.70M$3.72M$3.58M$3.03M-$4.26M$3.03M-$4.04M$6.00M
    Last 12 quarters

    Frequently Asked Questions About LFCR

    What is Lifecore Biomedical's annual revenue?

    Lifecore Biomedical reported revenue of $128.87M for the fiscal year ended May 31, 2025.

    How fast is Lifecore Biomedical's revenue growing?

    Revenue was up 0.5% for the fiscal year ended May 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 5.0%.

    Is Lifecore Biomedical profitable?

    No. Lifecore Biomedical reported net income of -$38.72M for the fiscal year ended May 31, 2025, with a net margin of -30.0%.

    How much free cash flow does LFCR generate?

    For the fiscal year ended May 31, 2025, operating cash flow of -$206.00K minus capital expenditures of $13.41M produced free cash flow of -$13.62M.

    How much debt does Lifecore Biomedical have?

    The balance sheet dated May 31, 2026 reported long-term debt of $135.59M, short-term debt of $1.33M and cash and equivalents of $17.47M.